Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Relat...(R Rodriguez CA Beard A Symonds WT ...)

Rodriguez CA, Beard A, Symonds WT, Hill G and Berrey MM (Pharmasset,

Christchurch Clinical Studies Trust and Roche Palo Alto).

-- Abstract P-262: The Mechanism of Action of Beta-D-2'-Deoxy-2'-fluoro-

2'-C-methylcytidine Involves a Second Metabolic Pathway Leading to

Beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-Triphosphate, a Potent

Inhibitor of the HCV RNA-Dependent RNA Polymerase. Murakami E, Niu C,

Bao H, Micolochick Steuer HM, Otto MJ and Furman PA (Pharmasset).

-- Abstract P-265: The Nucleoside Inhibitors R1479, PSI-6130, and NM107

have a Higher Genetic Barrier to Resistance than the Non-nucleoside

Inhibitor HCV-796 and the Protease Inhibitor VX-950. McCown M,

Rajyaguru S, Symons J, Cammack N and Najera I (Roche Palo Alto).

-- Abstract P-263: In Vitro Selection and Characterization of HCV

Replicons Resistant to PSI-6130. Ali S, Leveque V, LePogam S, Ma H,

Philipp F, Najera I, Klumpp K, Symons J, Cammack N and Jiang WR (Roche

Palo Alto).

-- Abstract P-259: Beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine

Phosphoramidates: Potent and Selective Inhibitors of HCV RNA

Replication. Sofia MJ, Wang P, Du J, Micolochick Steuer HM, Niu C,

Furman PA and Otto MJ (Pharmasset).

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is expected to enter Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by
'/>"/>